In a meeting with analysts, Novartis stated that it will prioritize the U.S. market and remains unfazed by drug pricing pushback. The company’s organizational update came after laws were passed in the Inflation Reduction Act to rein in drug prices in the world’s largest pharmaceutical market. (Reuters

Vaccinators around the country have reported weeks-long delays in shipments of Moderna’s updated COVID-19 vaccine boosters. The delays come after the Food and Drug Administration flagged concerns at a facility contracted to fill the Moderna’s new shots into vials. (CBS News)

Goldman Sachs said Revance Therapeutics is working on a Botox rival drug that could rally nearly 30%. The bank on Thursday initiated coverage of the company with a buy rating and $33 price target, which implies a more than 28% jump is possible for the stock in the next 12 months. Year to date, Revance has surged more than 58%. (CNBC)

Pfizer said it will supply 6 million Paxlovid treatments to Global Fund. More than 130 countries will have access to the antiviral pill based on “income classification and disease burden” through the Global Fund. (Axios)

A report detailed the hype and hazards of Hollywood’s secret new weight loss drug: Ozempic. The drug is an insulin regulator for the pre-diabetic, made by the Danish pharma juggernaut Novo Nordisk, whose primary side effect is dramatic weight loss. (Variety)